Rotarix Launch Planned For Second Half; GSK Touts Quick Dosing Schedule
Executive Summary
GlaxoSmithKline will launch its rotavirus gastroenteritis vaccine Rotarix in the U.S. in the second half of the year after FDA granted approval April 3. The two-course vaccine will offer a dosing advantage over Merck's existing rotavirus vaccine RotaTeq, which is administered over three courses